BAX - Baxter International Inc.
89.00 +0.37 (0.42%)
After hours: 6:08PM EDT
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 90.24 |
| Open | 89.23 |
| Bid | 88.00 x 800 |
| Ask | 89.00 x 1300 |
| Day's Range | 88.17 - 90.05 |
| 52 Week Range | 69.10 - 95.19 |
| Volume | 1,645,125 |
| Avg. Volume | 3,496,109 |
| Market Cap | 45.098B |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | 29.66 |
| EPS (TTM) | 2.99 |
| Earnings Date | Jul 30, 2020 |
| Forward Dividend & Yield | 0.98 (1.08%) |
| Ex-Dividend Date | Jun 04, 2020 |
| 1y Target Est | 97.31 |
Fair Value
Related Research
- Business Wire
Baxter to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Tuesday, June 9, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 9:40 a.m. Eastern Time.
- Barrons.com
May Was Bad for Dividends. But Here are 11 Big Companies That Raised Their Payouts.
The increases came in a month when many other companies said they would maintain their payouts at current levels or, worse, suspend them.
- Zacks
Why Is Baxter (BAX) Up 1.4% Since Last Earnings Report?
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Insider Monkey
Hedge Funds Are Flocking Into Baxter International Inc. (BAX)
In this article you are going to find out whether hedge funds think Baxter International Inc. (NYSE:BAX) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
- GuruFocus.com
Al Gore Sells Credicorp and Adds 3 New Holdings
Former US vice president's firm releases 1st-quarter portfolio Continue reading...
- GuruFocus.com
Point72 Asset Management Buys Micron Technology, Baxter
Firm's largest buys of the 1st quarter Continue reading...
- Zacks
Baxter Receives CE Marking for Evo IQ Syringe Infusion System
Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.
- Reuters
Mexico orders probe into alleged graft linked to ex-president
Mexican President Andres Manuel Lopez Obrador on Wednesday ordered an investigation into allegations the former government irregularly awarded lucrative contracts to a firm reportedly owned by the family of his predecessor, Enrique Pena Nieto. "We have to investigate if President Pena Nieto is involved and see how long the company has been operating, what contracts it received ... if they were awarded directly, through tenders," Lopez Obrador said at his daily press conference. Baxter and Plasti-Esteril were not immediately available to comment.
- Moody's
Baxter International Inc. -- Moody's announces completion of a periodic review of ratings of Baxter International Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Baxter International Inc. New York, May 20, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Baxter International Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Business Wire
Baxter Receives CE Marking and Australian Regulatory Approval for Evo IQ Syringe Infusion System, Building on Smart Pump Platform
Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced CE marking and regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for the Evo IQ Syringe Infusion System. The company expects hospitals in the United Kingdom, Ireland, Greece, Australia and New Zealand to be among the first to receive the new system, with additional countries to follow in a series of planned regulatory submissions.
- GuruFocus.com
Daniel Loeb Exits Campbell Soup and Trims Baxter in the 1st Quarter
Third Point’s top 3 sells for the quarter outweigh its top 2 new buys Continue reading...
- GuruFocus.com
Third Point Exits Campbell Soup, Trims Baxter International
Firm's largest sales of the 1st quarter Continue reading...
- Thomson Reuters StreetEvents
Edited Transcript of BAX earnings conference call or presentation 30-Apr-20 12:30pm GMT
Q1 2020 Baxter International Inc Earnings Call
- Business Wire
Baxter Announces Results of Clinical Trial on Benefits of Dynamic Fluid Management in Septic Shock Patients
Results published in the CHEST Journal demonstrate benefits of using dynamic measures to guide fluid therapy decisions.
- MarketWatch
Baxter boosts dividend by 11%, but still yields less than health care ETF
Baxter International Inc. said Tuesday it was raising its quarterly dividend by 11%, to 24.5 cents a share from 22 cents. The health care products company's new dividend will be payable July 1 to shareholders of record on June 5. Based on Monday's stock closing price of $87.27, the new annual dividend rate implies a dividend yield of 1.12%, compared with the yield for the SPDR Health Care Select Sector ETF of 1.62% and the implied yield for the S&P 500 of 2.06%. The stock, which rose 0.8% in premarket trading, has gained 4.4% year to date through Monday, while the health care ETF has lost 4.0% and the S&P 500 has declined 12.0%.
- Business Wire
Baxter Increases Dividend and Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced an increase in the company’s quarterly cash dividend to a rate of $0.245 per share of common stock. This represents an approximately 11% increase over the previous quarterly dividend rate of $0.22 per share. Baxter’s Board of Directors declared the dividend payable on July 1, 2020, to stockholders of record as of June 5, 2020. The indicated annual dividend rate is now $0.98 per share of common stock.
- Insider Monkey
Were Hedge Funds Right About Baxter International (BAX)?
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- Motley Fool
Baxter International Inc (BAX) Q1 2020 Earnings Call Transcript
Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer. On the call this morning, we will be discussing Baxter's first quarter 2020 financial results.
- Motley Fool
Baxter Beats Q1 Estimates as COVID-19 Boosts Sales
The giant healthcare company saw increased demand in Q1 for several products due to the coronavirus pandemic.
- Business Wire
Baxter Reports First-Quarter 2020 Results
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2020.
- Business Wire
Baxter to Present at the UBS Virtual Global Healthcare Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 via webcast. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:00 a.m. Eastern Time.
- Business Wire
Baxter to Present at the Virtual BofA Securities 2020 Health Care Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the virtual BofA Securities 2020 Health Care Conference via webcast on Tuesday, May 12, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:20 a.m. Eastern Time.
- Business Wire
Baxter Obtains U.S. FDA Emergency Use Authorization for Oxiris Blood Purification Filter for COVID-19 Treatment
Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received emergency use authorization (EUA) from the U.S. FDA for the company’s Oxiris filter set to treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy (CRRT).
- Business Wire
Baxter to Host First-Quarter 2020 Financial Results Conference Call for Investors
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its first-quarter 2020 financial results on Thursday, April 30, 2020, at 7:30 a.m. Central Time.
- Investor's Business Daily
Medical Product Maker Baxter Near Buy Zone, Hiring Employees; Earnings Due
Baxter International is building a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Apr. 30.
